Tolcapone

托卡朋

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameTolcapone
Drug Alias Name托可朋tolcaponumtolcaponaTasmarRo-40-7592
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCatechol-O-methyl transferase inhibitors
TargetsCatechol-O-methyl transferase
Therapy Area/IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityObsessive-Compulsive Disorder +[11] 
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryEU
Original Approved Date1997/08/27
Country/TerritoryUnited StatesSwitzerlandSpain +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesViatris Healthcare LtdUniversity Of Colorado DenverUniversity Of Navarra +[6] 
Inactive CompaniesUniversity of ZurichThe University Of ChicagoColumbia University +[7] 
Active IndicationsSchizophreniaAttention Deficit Disorder with HyperactivityAlcoholism +[4] 
Inactive IndicationsObsessive-Compulsive DisorderGamblingTobacco Use Disorder +[7] 

Other Information

ATC CodeN04BX01
Related LinksWikipediaDrugBankKEGG